#Hyperk - Twitter Hashtag

5 months ago

Precision Before Discovery: A Conversation with Dr. Yoshikazu Nagai Read more: https://t.co/8hB84FX1h7 #NeutrinoPhysics #ParticlePhysics #HyperK #T2K #CERN #OpenScience

NET8_Token's tweet photo. Precision Before Discovery: A Conversation with Dr. Yoshikazu Nagai

Read more: https://t.co/8hB84FX1h7

#NeutrinoPhysics #ParticlePhysics #HyperK #T2K #CERN #OpenScience https://t.co/pltf1xTcCQ

0

2

1

42

La chuleta de Osler 🇵🇪🇵🇸 @chuletadeosler

9 months ago

Hiperpotasemia: clinixa y cambios ECG. #hyperK

1

123

40

33

3K

cardio-met

@cardiomet_CE

over 3 years ago

21) Further clinical & practice context about nonsteroidal #MRA in #T2D with #CKD: 1. Risk of #HyperK & mitigation 2. Use in older adults 3. Blood Pressure Effects 4. Use a #flozin, a nonsteroidal #MRA or both? We will consider them all in turn!

1

2

0

753

cardio-met

@cardiomet_CE

over 3 years ago

15) #FIGARODKD was also a practice changing trial: 🔎#CVevents & #HF (primary outcome) were ↓ by #MRA in patients w/ #T2D & #CKD 🔎Trend for benefit for 2nd #kidney composite & 36% ↓ in #ESKD 🔎 ↑ #HyperK but NO #AKI risk 🔓 https://t.co/fQfRwb3UfE 🔓 https://t.co/HNuzbBG2IC

cardiomet_CE's tweet photo. 15) #FIGARODKD was also a practice changing trial:
🔎#CVevents & #HF (primary outcome) were ↓ by #MRA in patients w/ #T2D & #CKD
🔎Trend for benefit for 2nd #kidney composite & 36% ↓ in #ESKD
🔎 ↑ #HyperK but NO #AKI risk
🔓 https://t.co/fQfRwb3UfE
🔓 https://t.co/HNuzbBG2IC https://t.co/eQEZMFCymQ

1

2

0

1K

cardio-met

@cardiomet_CE

over 3 years ago

14) Adverse events were similar between nonsteroidal #MRA and placebo except for ▶️#HyperK (hyperkalemia) related adverse events, whose risk factors, clinical significance and management we will consider at length later in this #tweetorial 🆘 #AKI(Acute Kidney Injury) did NOT ↑

cardiomet_CE's tweet photo. 14) Adverse events were similar between nonsteroidal #MRA and placebo except for
▶️#HyperK (hyperkalemia) related adverse events, whose risk factors, clinical significance and management we will consider at length later in this #tweetorial
🆘 #AKI(Acute Kidney Injury) did NOT ↑ https://t.co/XVcbIB1QyZ

1

2

0

968

@CKD_ce

@ckd_ce

over 3 years ago

29) Use the #FIDELIODKD protocol to build your #HyperK strategy: ✔️K & maintain #MRA dose as long as K <5.5 (start when K<4.8) 🔎alternative causes that may have led to ⬆️ K (> 5.5) Temporarily 🛑 #finerenone for 72hr & restart at lower dose if K ≤ 5 🔓 https://t.co/N1ERNMgnoh

ckd_ce's tweet photo. 29) Use the #FIDELIODKD protocol to build your #HyperK strategy:
✔️K & maintain #MRA dose as long as K <5.5 (start when K<4.8)
🔎alternative causes that may have led to ⬆️ K (> 5.5)
Temporarily 🛑 #finerenone for 72hr & restart at lower dose if K ≤ 5
🔓 https://t.co/N1ERNMgnoh https://t.co/aIN8vWpgsd

1

2

1

0

667

@CKD_ce

@ckd_ce

over 3 years ago

28) Strategies to manage #HyperK risk of nonsteroidal #MRA are: 💡Apply the protocol used in the #finerenone trials: 1. ➡️#SafetyFirst : measure the potassium 2. Protocolize ↓ the dose or 🛑the MRA 🛠️Diuretics/#flozin to eliminate K through the kidneys 🛠️Use a potassium binder

1

0

499

@CKD_ce

@ckd_ce

over 3 years ago

27) To sum up: ➡️#HyperK may occur w/ (↑risk) or w/out MRA under ACEi/ARB in #CKD due to #ENACchannel 🔓 https://t.co/z65jk4PkeH ➡️Continued use of MRAs is required for cardiovascular & kidney benefit ➡️Management of HyperK allows the safe use of MRAs, but how can we do this?

ckd_ce's tweet photo. 27) To sum up:
➡️#HyperK may occur w/ (↑risk) or w/out MRA under ACEi/ARB in #CKD due to #ENACchannel
🔓 https://t.co/z65jk4PkeH
➡️Continued use of MRAs is required for cardiovascular & kidney benefit
➡️Management of HyperK allows the safe use of MRAs, but how can we do this? https://t.co/wtC84bD0lX

1

0

481

@CKD_ce

@ckd_ce

over 3 years ago

26) Risk factors for #HyperK on nonsteroidal #MRA: 🔓 https://t.co/bnBlYk1VN7 ▶️ Males ▶️ K > 4.5 (FDA label: initiate #finerenone if K ≤ 5.0) ▶️ eGFR < 45 ▶️ Higher UACR ▶️ ↑ K or ↓ eGFR at months 1&4 predicted long term risk *Diuretics & SGLT2i/#SGLT2is were PROTECTIVE*

ckd_ce's tweet photo. 26) Risk factors for #HyperK on nonsteroidal #MRA:
🔓 https://t.co/bnBlYk1VN7
▶️ Males
▶️ K > 4.5 (FDA label: initiate #finerenone if K ≤ 5.0)
▶️ eGFR < 45
▶️ Higher UACR
▶️ ↑ K or ↓ eGFR at months 1&4 predicted long term risk
*Diuretics & SGLT2i/#SGLT2is were PROTECTIVE* https://t.co/c7OcbJdw14

1

2

0

711

@CKD_ce

@ckd_ce

over 3 years ago

25a) ▶️ #HyperK is frequent in pts with #T2D & #CKD on max #ACEi/#ARB(those on placebo had rates 9-10% for K > 5.5) 🔓 https://t.co/bnBlYk1VN7

1

0

488

@CKD_ce

@ckd_ce

over 3 years ago

21) Further clinical & practice context about nonsteroidal #MRA in #T2D with #CKD: 1. Risk of #HyperK & mitigation 2. Use in older adults 3. Blood Pressure Effects 4. Use a #flozin, a nonsteroidal #MRA or both? We will consider them all in turn!

1

2

1

0

546

@CKD_ce

@ckd_ce

over 3 years ago

15) #FIGARODKD was also a practice changing trial: 🔎#CVevents & #HF (primary outcome) were ↓ by #MRA in patients w/ #T2D & #CKD 🔎Trend for benefit for 2nd #kidney composite & 36% ↓ in #ESKD 🔎 ↑ #HyperK but NO #AKI risk 🔓 https://t.co/kSVp01OSCz 🔓 https://t.co/173HcX8Cpf

ckd_ce's tweet photo. 15) #FIGARODKD was also a practice changing trial:
🔎#CVevents & #HF (primary outcome) were ↓ by #MRA in patients w/ #T2D & #CKD
🔎Trend for benefit for 2nd #kidney composite & 36% ↓ in #ESKD
🔎 ↑ #HyperK but NO #AKI risk
🔓 https://t.co/kSVp01OSCz
🔓 https://t.co/173HcX8Cpf https://t.co/iU9XQzGzqe

1

2

1

0

581

@CKD_ce

@ckd_ce

over 3 years ago

14) Adverse events were similar between nonsteroidal #MRA and placebo except for ▶️#HyperK (hyperkalemia) related adverse events, whose risk factors, clinical significance and management we will consider at length later in this #tweetorial 🆘#AKI (Acute Kidney Injury) did NOT ↑

ckd_ce's tweet photo. 14) Adverse events were similar between nonsteroidal #MRA and placebo except for
▶️#HyperK (hyperkalemia) related adverse events, whose risk factors, clinical significance and management we will consider at length later in this #tweetorial
🆘#AKI (Acute Kidney Injury) did NOT ↑ https://t.co/hi8UGTCkLY

1

3

1

0

555

Giuseppe Galati @GiuseppeGalati_

over 3 years ago

🔥 Another proof of benefit of #ARNI in #HFmrEF & #HFpEF especially after a recent #HF 🏥 ❤️‍🔥 #ARNI is more effective in ⬇️ Total #HF events + #CV ☠️ 🍀 #ARNI is safer (safer!) than #ARB about #renal events & function & #hyperk+ https://t.co/T7oWyKbHOT @mvaduganathan @gcfmd

GiuseppeGalati_'s tweet photo. 🔥 Another proof of benefit of #ARNI in #HFmrEF & #HFpEF especially after a recent #HF 🏥
❤️‍🔥 #ARNI is more effective in ⬇️ Total #HF events + #CV ☠️
🍀 #ARNI is safer (safer!) than #ARB about #renal events & function & #hyperk+

https://t.co/T7oWyKbHOT

@mvaduganathan @gcfmd https://t.co/CVohy6ptnz

Alfonso Valle @ValleAlfonso

over 3 years ago

Pooled of PARAGLIDE-HF & PARAGON-HF 👉Sacubitril/valsartan ⤵️ CV & renal events vs valsartan among patients with HFmr/HFpEF 👉⤵️ CV events first observed within 1-2 weeks of treatment initiation. 👉CV benefits most apparent in patients with an LVEF below normal. Sacubitril/valsartan ⤵️ risks of WRF #HeartFailure2023 @mvaduganathan

ValleAlfonso's tweet photo. Pooled of PARAGLIDE-HF & PARAGON-HF
👉Sacubitril/valsartan ⤵️ CV & renal events vs valsartan among patients with HFmr/HFpEF
👉⤵️ CV events first observed within 1-2 weeks of treatment initiation.
👉CV benefits most apparent in patients with an LVEF below normal.
Sacubitril/valsartan ⤵️ risks of WRF #HeartFailure2023 @mvaduganathan

0

105

61

15

23K

1

50

18

5

9K

CLUB TV @ClubTvOfc

over 3 years ago

[BTS] Olha só quem garantiu o MVP desta noite 💜 #HyperK @BTSBRpokemon

0

8

0

385

VIIT Pune @viit_pune

almost 4 years ago

Congratulations to Team VIIT on successfully organising the first Indo-Japan Workshop on Hyper-K! #IndoJapanWorkshop #HyperK #congratulations #viitpune #engineering #engineeringstudentslife #informationtechnology #punekars #punediaries #puneengineering #pune #punecity

viit_pune's tweet photo. Congratulations to Team VIIT on successfully organising the first Indo-Japan Workshop on Hyper-K!

#IndoJapanWorkshop #HyperK #congratulations #viitpune #engineering #engineeringstudentslife #informationtechnology #punekars #punediaries #puneengineering #pune #punecity https://t.co/p6YB9zvccO

0

5

0

219

Jonathan Chávez

@JonathanNefro

almost 4 years ago

En enfermedad renal crónica G3, un monograma predice que paciente desarrollará hiperkalemia (>5.5 mmol/L) en los siguientes 6 meses, con una habilidad discriminatoria de 75% #hyperK Kidney360 2022 doi:10.34067/KID.0004752022

JonathanNefro's tweet photo. En enfermedad renal crónica G3, un monograma predice que paciente desarrollará hiperkalemia (>5.5 mmol/L) en los siguientes 6 meses, con una habilidad discriminatoria de 75%

#hyperK

Kidney360 2022
doi:10.34067/KID.0004752022 https://t.co/2StEYHzQPy

1

49

12

6

0

Emilio Sánchez @EmiliSanAlv

about 4 years ago

@dvdrry @NephroGuy @bourneauguste @AJKDonline @JoanneBargman @UofTNephrology @caioqualunque As @dvdrry says we uses high doses of diuretics but not so high. Sic tablets dayly of Furosemide or Torasemide & MRA sometimes as coadyuvant as #HyperK is not a problem in PD

0

1

0

Jule R O G Santos @julesantosER

about 4 years ago · Brasília

Uma história com final feliz! #hyperk #FOAMed #FOAMedBR 👉🏽 https://t.co/XacPTUsyOj

1

6

0

1

0

Jonathan Chávez

@JonathanNefro

about 4 years ago

Utilizar el ligador de potasio intestinal zirconio ciclosilicato en pacientes con enfermedad renal crónica e hiperkalemia es costo efectivo, al ↑€14,838/QALY, derivado de ↓ los eventos de hiperkalemia y hospitalizaciones #hyperk BMC Nephrology 2022 https://t.co/7Nu4yyqtxH

JonathanNefro's tweet photo. Utilizar el ligador de potasio intestinal zirconio ciclosilicato en pacientes con enfermedad renal crónica e hiperkalemia es costo efectivo, al ↑€14,838/QALY, derivado de ↓ los eventos de hiperkalemia y hospitalizaciones

#hyperk

BMC Nephrology 2022
https://t.co/7Nu4yyqtxH https://t.co/QpZYyXoUwD

1

29

12

1

0

Top Tweets for #Hyperk

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users